Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA's Policy Development and Coordination Staff

Executive Summary

Director David Adams is leaving the agency in May to join the Washington, D.C. office of Morgan, Lewis & Bockius, an international law firm. Adams, 42, joined FDA in 1978 as associate chief counsel for enforcement and trial attorney. From 1985 to 1992, Adams served as associate chief counsel for drugs and, in January 1992, went to the Office of the Commissioner. As an FDA litigator, Adams spearheaded a variety of enforcement and defensive cases including the 1991 consent decree with Syntex over Naprosyn promotions. He was the primary attorney handling the generic drug controversies and the final regs implementing Title I of the Waxman/Hatch Act. Adams also was involved in development of FDA policies on application integrity, industry-supported scientific and educational activities, pharmacist compounding and accelerated drug approval

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts